Inspiremd Inc (NSPR)

$2.72 +0.04 (1.65%)
Market Cap 69.91M
Revenue (ttm) 6.21M
Net Income (ttm) -19.92M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -320.77%
Debt to Equity Ratio 0.00
Volume 42,300
Avg Vol 51,892
Day's Range N/A - N/A
Shares Out 26.08M
Stochastic %K 44%
Beta 0.99
Analysts Strong Sell
Price Target $4.75

Latest News on NSPR

InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR)

Dec 9, 2024, 7:00 AM EST - 5 weeks ago

InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR)

InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors

Nov 25, 2024, 4:05 PM EST - 7 weeks ago

InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors

InspireMD, Inc. (NSPR) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 10:20 AM EST - 2 months ago

InspireMD, Inc. (NSPR) Q3 2024 Earnings Call Transcript

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 8, 2024, 5:30 PM EST - 2 months ago

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System

Oct 15, 2024, 7:00 AM EDT - 3 months ago

InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System

InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System

Oct 7, 2024, 7:00 AM EDT - 3 months ago

InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System

InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System

Sep 16, 2024, 7:00 AM EDT - 4 months ago

InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System

InspireMD, Inc. (NSPR) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 8:58 AM EDT - 5 months ago

InspireMD, Inc. (NSPR) Q2 2024 Earnings Call Transcript

InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 6, 2024, 8:09 AM EDT - 5 months ago

InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update

InspireMD Congratulates CREST-2 Investigators on Completion of Trial Enrollment

Aug 5, 2024, 7:00 AM EDT - 5 months ago

InspireMD Congratulates CREST-2 Investigators on Completion of Trial Enrollment

InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6th

Jul 30, 2024, 7:00 AM EDT - 6 months ago

InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6th

InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024

May 28, 2024, 8:53 AM EDT - 8 months ago

InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024

InspireMD Inc. (NSPR) Q1 2024 Earnings Call Transcript

May 14, 2024, 10:50 AM EDT - 8 months ago

InspireMD Inc. (NSPR) Q1 2024 Earnings Call Transcript

InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update

May 14, 2024, 7:00 AM EDT - 8 months ago

InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update

InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th

May 7, 2024, 7:00 AM EDT - 9 months ago

InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th

InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference

Apr 3, 2024, 8:59 AM EDT - 10 months ago

InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference

InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024

Mar 26, 2024, 7:00 AM EDT - 10 months ago

InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024

InspireMD Inc. (NSPR) Q4 2023 Earnings Call Transcript

Mar 6, 2024, 11:30 AM EST - 11 months ago

InspireMD Inc. (NSPR) Q4 2023 Earnings Call Transcript

InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Mar 6, 2024, 7:00 AM EST - 11 months ago

InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th

Feb 28, 2024, 7:00 AM EST - 11 months ago

InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th

InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System

Feb 12, 2024, 7:00 AM EST - 1 year ago

InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System

InspireMD Receives CE Mark Recertification Under EU's New Medical Device Regulation (MDR) Regulatory Framework

Jan 31, 2024, 7:00 AM EST - 1 year ago

InspireMD Receives CE Mark Recertification Under EU's New Medical Device Regulation (MDR) Regulatory Framework

InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America

Jan 3, 2024, 7:00 AM EST - 1 year ago

InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America

InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System

Dec 20, 2023, 7:00 AM EST - 1 year ago

InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System

InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions

Nov 27, 2023, 7:00 AM EST - 1 year ago

InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions

InspireMD Inc. (NSPR) Q3 2023 Earnings Call Transcript

Nov 6, 2023, 11:09 AM EST - 1 year ago

InspireMD Inc. (NSPR) Q3 2023 Earnings Call Transcript

InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 6, 2023, 7:00 AM EST - 1 year ago

InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update

InspireMD to Participate in Upcoming November Investor Conferences

Nov 2, 2023, 8:00 AM EDT - 1 year ago

InspireMD to Participate in Upcoming November Investor Conferences

InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23

Nov 1, 2023, 2:19 PM EDT - 1 year ago

InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23

InspireMD to Report Third Quarter 2023 Financial Results and Provide Corporate Business Update on Monday, November 6th

Oct 30, 2023, 9:21 AM EDT - 1 year ago

InspireMD to Report Third Quarter 2023 Financial Results and Provide Corporate Business Update on Monday, November 6th

InspireMD Supports CMS' Final National Coverage Determination (NCD) Expanding Coverage of Carotid Stenting (CAS) to Include Both Asymptomatic and Standard Risk Patients

Oct 12, 2023, 7:00 AM EDT - 1 year ago

InspireMD Supports CMS' Final National Coverage Determination (NCD) Expanding Coverage of Carotid Stenting (CAS) to Include Both Asymptomatic and Standard Risk Patients

InspireMD Announces Senior Leadership Changes to Support Commercial Growth Initiatives

Oct 3, 2023, 7:00 AM EDT - 1 year ago

InspireMD Announces Senior Leadership Changes to Support Commercial Growth Initiatives

InspireMD Announces Abstract of 30-Day Results from the C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at VIVA23

Aug 31, 2023, 8:00 AM EDT - 1 year ago

InspireMD Announces Abstract of 30-Day Results from the C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at VIVA23

InspireMD Inc. (NSPR) Q2 2023 Earnings Call Transcript

Aug 8, 2023, 11:18 AM EDT - 1 year ago

InspireMD Inc. (NSPR) Q2 2023 Earnings Call Transcript

InspireMD Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 8, 2023, 7:00 AM EDT - 1 year ago

InspireMD Reports Second Quarter 2023 Financial Results and Provides Business Update

InspireMD to Report Second Quarter 2023 Financial Results and Provide Corporate Business Update on Tuesday, August 8th

Jul 25, 2023, 8:00 AM EDT - 1 year ago

InspireMD to Report Second Quarter 2023 Financial Results and Provide Corporate Business Update on Tuesday, August 8th

InspireMD Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial

Jun 26, 2023, 8:00 AM EDT - 1 year ago

InspireMD Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial

InspireMD Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

May 18, 2023, 8:00 AM EDT - 1 year ago

InspireMD Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

InspireMD, Inc. (NSPR) Q1 2023 Earnings Call Transcript

May 16, 2023, 11:24 AM EDT - 1 year ago

InspireMD, Inc. (NSPR) Q1 2023 Earnings Call Transcript

InspireMD Reports First Quarter 2023 Financial Results and Provides Business Update

May 16, 2023, 7:00 AM EDT - 1 year ago

InspireMD Reports First Quarter 2023 Financial Results and Provides Business Update

InspireMD Announces Private Placement of Up to $113.6 Million

May 15, 2023, 8:00 AM EDT - 1 year ago

InspireMD Announces Private Placement of Up to $113.6 Million

InspireMD Announces May 16, 2023 as New Date for First Quarter 2023 Results Conference Call and Webcast

May 12, 2023, 4:05 PM EDT - 1 year ago

InspireMD Announces May 16, 2023 as New Date for First Quarter 2023 Results Conference Call and Webcast

InspireMD Announces May 15th as New Date for First Quarter 2023 Financial Results and Corporate Business Update

May 5, 2023, 8:00 AM EDT - 1 year ago

InspireMD Announces May 15th as New Date for First Quarter 2023 Financial Results and Corporate Business Update

InspireMD Announces Successful First-in-Human Procedure Utilizing CGuard Prime, its Next Generation Carotid Artery Stent (CAS) Platform

May 1, 2023, 8:00 AM EDT - 1 year ago

InspireMD Announces Successful First-in-Human Procedure Utilizing CGuard Prime, its Next Generation Carotid Artery Stent (CAS) Platform

InspireMD to Report First Quarter 2023 Financial Results on May 9, 2023, and Provide Corporate Business Update

Apr 27, 2023, 8:00 AM EDT - 1 year ago

InspireMD to Report First Quarter 2023 Financial Results on May 9, 2023, and Provide Corporate Business Update

InspireMD, Inc. (NSPR) Q4 2022 Earnings Call Transcript

Mar 30, 2023, 10:34 AM EDT - 1 year ago

InspireMD, Inc. (NSPR) Q4 2022 Earnings Call Transcript

InspireMD Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update

Mar 30, 2023, 7:00 AM EDT - 1 year ago

InspireMD Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update

InspireMD Announces Promotion of Andrea Tommasoli to Chief Operating Officer

Mar 20, 2023, 8:00 AM EDT - 1 year ago

InspireMD Announces Promotion of Andrea Tommasoli to Chief Operating Officer

InspireMD to Report Fourth Quarter and Full-Year 2022 Financial Results on March 30, 2023, and Provide a Corporate Business Update

Mar 2, 2023, 8:00 AM EST - 2 years ago

InspireMD to Report Fourth Quarter and Full-Year 2022 Financial Results on March 30, 2023, and Provide a Corporate Business Update

InspireMD Announces Hiring of Medical Device Commercial Veteran Shane Gleason as General Manager of North America and VP of Global Marketing

Feb 14, 2023, 8:00 AM EST - 2 years ago

InspireMD Announces Hiring of Medical Device Commercial Veteran Shane Gleason as General Manager of North America and VP of Global Marketing